Any news for July for LLY

Here is some news about LLY for July:

1. Eli Lilly's Taltz Fails to Meet Primary Endpoint in Phase 3 Trial: Eli Lilly announced on July 5, 2024, that its drug Taltz did not meet the primary endpoint in a Phase 3 trial for the treatment of diabetic macular edema (DME). This news could have implications for the company's DME treatment strategy and investor sentiment.
2. Eli Lilly's M&A Moves in July: Eli Lilly has been active in the mergers and acquisitions space in July, with two notable deals. On July 10, 2024, the company announced the acquisition of AnPac Bio-Medical Science's cancer diagnostic assets, and on July 24, 2024, Eli Lilly entered into an agreement to acquire Immunogen for $8.1 billion. These moves reflect the company's strategy to bolster its pharmaceutical portfolio and potentially impact its stock price.